Rituximab Treatment for Rheumatoid Arthritis-Associated Interstitial Lung Disease

Guideline-Based Support for Rituximab in RA-ILD

The American College of Rheumatology/American College of Chest Physicians guidelines conditionally recommend rituximab as a preferred first-line treatment option for RA-ILD, particularly when active inflammatory arthritis is present, with potential benefits for mortality and ILD progression by reducing disease activity 1
For RA-ILD with active inflammatory features, rituximab may be chosen over mycophenolate as the preferred agent, according to the American College of Rheumatology/American College of Chest Physicians guidelines 1
The American College of Rheumatology/American College of Chest Physicians guidelines explicitly state that the hierarchy of treatment options should not be used by insurers to mandate specific prescribing order, and clinicians must retain latitude to prescribe recommended medications based on individual patient factors and preferences 1

The American College of Rheumatology recommends continuation of rituximab in patients with RA-ILD who have demonstrated a positive clinical response to treatment, as seen in this patient with documented clinical improvement in symptoms 1

The American College of Rheumatology conditionally recommends rituximab as a treatment option for progressive RA-ILD if not already used as first-line therapy, with a moderate strength of evidence 3
The American College of Rheumatology conditionally recommends pirfenidone as add-on therapy specifically for progressive RA-ILD, with a moderate strength of evidence 3
Nintedanib and tocilizumab are additional options for progressive RA-ILD, according to the American College of Rheumatology guidelines, with a moderate strength of evidence 3

The patient has no joint pain or swelling, indicating good control of both articular and pulmonary manifestations, and rituximab has an acceptable safety profile in RA-ILD, according to the American College of Rheumatology guidelines 1

The patient's serology profile indicates aggressive autoimmune disease requiring ongoing immunosuppression, and the American College of Rheumatology guidelines support the use of rituximab in this context 1

The American College of Rheumatology guidelines advise against discontinuing effective therapy based solely on insurance criteria when clinical response is documented and guidelines support use, with a high strength of evidence 1
The American College of Rheumatology guidelines note that methotrexate is advised against for SARD-ILD treatment, though it may be appropriate for extrapulmonary manifestations, with a moderate strength of evidence 4, 1

The American College of Rheumatology recommends pulmonary function tests (FVC and DLCO) every 3-6 months to objectively assess disease progression, with a moderate strength of evidence 2
The American College of Rheumatology recommends high-resolution CT at baseline and annually or with significant PFT changes, with a moderate strength of evidence 2
The American College of Rheumatology recommends complete blood count every 2-4 months for immunosuppression monitoring, with a moderate strength of evidence 2